FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma

Last Updated: Tuesday, April 12, 2022

Based on data from the randomized, open-label, multicenter ZUMA-7 trial, the FDA approved the use of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel in adult patients with large B-cell lymphoma refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

U.S. Food and Drug Administration

European Society for Medical Oncology (ESMO) Congress 2024 Abstract

806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)

The Oncologist

Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma 

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management

Leukemia

Treatment resistance in diffuse large B-cell lymphoma

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

OncoImmunology

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

Cancers

Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

DLBCL Resource Center